MADRID, Dec 27 (Reuters) - Spanish blood company Grifols (GRF.MC: Quote, Profile , Research) said on Wednesday the Food and Drug Administration had given it authorisation to sell its intravenous immunoglobulin (IGIV) product Flebogamma DIF in the United States.
